NR4A1 and breast cancer: Elevated serum uPA predicted poor clinical outcome best in patients with HER2-positive disease and – with regard to overall survival – in triple negative tumors while no statistical significance was observed in the largest subgroup of patients with hormone receptor positive HER2-negative BC (Table 3).